ABX464 has completed a Phase 2a proof-of-concept study, ABX464-101, aimed at evaluating the safet and efficacy of ABX464 50 mg given once daily versus placebo for two months in subjects with moderate-to-severe active ulcerative colitis (UC) who have failed or are intolerant to immunomodulators, anti-TNFα, vedolizumab and/or corticosteroids. This study revealed a statistically significant difference … Continue reading ABX464 for UC